Compare SPRO & SORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | SORA |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.0M | 56.7M |
| IPO Year | 2017 | 2024 |
| Metric | SPRO | SORA |
|---|---|---|
| Price | $0.94 | $2.40 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.33 | N/A |
| AVG Volume (30 Days) | ★ 320.0K | 13.4K |
| Earning Date | 11-12-2026 | 04-30-2027 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,802,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $0.95 | $1.25 |
| 52 Week High | $3.08 | $4.49 |
| Indicator | SPRO | SORA |
|---|---|---|
| Relative Strength Index (RSI) | 34.32 | 51.86 |
| Support Level | N/A | $1.99 |
| Resistance Level | $1.27 | $2.56 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 3.18 | 77.50 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.